Search | Clinical Trials Finder

Conditions: Bipolar Disorder, Cocaine Dependence
Interventions: Lamotrigine, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: SHP465; Drug
Lead sponsor: Shire; Industry
Eligibility: 4 Years to 5 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 8
States / cities: Little Rock, Arkansas • Orlando, Florida • Evansville, Indiana + 5 more

Conditions: Attention-deficit/Hyperactivity Disorder
Interventions: Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 81
States / cities: Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 68 more

Conditions: Shock
Interventions: USCOM; Device
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Traumatic Brain Injury (TBI), Attention Deficit Hyperactivity Disorder (ADHD), Head Injury, Brain Concussion, Head Injuries, Closed
Interventions: AIM; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 10 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: ADHD
Interventions: galantamine HBr; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 58 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
Interventions: NRP104; Drug
Lead sponsor: New River Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus Type 2
Interventions: exenatide, taspoglutide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 87
States / cities: Haleyville, Alabama • Mobile, Alabama • Montgomery, Alabama + 78 more

Conditions: Drug Resistant Partial Onset Seizure
Interventions: ganaxolone; Drug
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Santa Monica, California • Lexington, Kentucky • Golden Valley, Minnesota + 2 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Atomoxetine Hydrochloride; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: ADHD
Interventions: Mixed amphetamine salts (ADDERALL XR), Atomoxetine hydrochloride; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Secondary Acute Myeloid Leukemia
Interventions: Venetoclax, FLAG or CLAG Protocol; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: OPDC-34712, Placebo, Stimulant Therapy; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 35
States / cities: Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more

Conditions: Neurocognitive Impairment, Acute Lymphoblastic Leukemia
Interventions: Neurocognitive and behavioral evaluation; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 8 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Malignant Pleural Effusion
Interventions: Talc; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: NFC-1 100 mg, NFC-1 200 mg, NFC-1 400 mg, NFC-1 800 mg; Drug
Lead sponsor: Aevi Genomic Medicine, LLC, a Cerecor company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 3
States / cities: Maitland, Florida • Miami, Florida • Las Vegas, Nevada

Conditions: Multiple Sclerosis
Interventions: Teriflunomide, Placebo (for teriflunomide), Glatiramer Acetate (GA); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Non-Small Cell Lung Cancer
Interventions: Ranpirnase; Drug
Lead sponsor: Tamir Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Beverly Hills, California • Grand Rapids, Michigan • Great Falls, Montana + 3 more

Conditions: Cerebrovascular Accident, Transient Ischemic Attack, ADHD
Interventions: atomoxetine, Stimulants, No intervention (general population); Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 72,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Breast Cancer Female
Interventions: OCT- based investigational imaging device; Device
Lead sponsor: Perimeter Medical Imaging; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cottonwood, Arizona

Conditions: Type 2 Diabetes Mellitus
Interventions: Bexagliflozin, Placebo for Bexagliflozin, Glimepiride, Placebo for Glimepiride; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 11
States / cities: Birmingham, Alabama • Huntington Park, California • Los Angeles, California + 8 more

Conditions: Adult Attention Deficit Hyperactivity Disorder
Interventions: Serdexmethylphenidate/dexmethylphenidate; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Tafasitamab, Tafasitamab plus lenalidomide; Drug
Lead sponsor: MorphoSys AG; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 23
States / cities: Tucson, Arizona • Anaheim, California • Duarte, California + 20 more

Conditions: Adult Attention Deficit Hyperactivity Disorder
Interventions: Dasotraline, Placebo; Drug · Other
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 636 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 59
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 48 more

Search by objective public record fields.

Lamotrigine add-on Therapy for Bipolar Disorder and Cocaine Dependency

Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

The Use of the USCOM Device in Addition to Cardiac Ultrasound in Patients Undergoing Treatment for Undifferentiated Shock

Attention Intervention Management

A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder

Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures

Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD

Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD

A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors

Randomized Controlled Trial of Talc Instillation In Addition To Daily Drainage Through a Tunneled Pleural Catheter to Improve Rates of Outpatient Pleurodesis in Patients With Malignant Pleural Effusion

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis

A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer

Safety Study of Atomoxetine and Cerebrovascular Outcomes

Intraoperative Use of an Optical Coherence Tomography (OCT) Imaging System to Guide Additional Margin Cavity Shaves in Breast Conserving Surgery (BCS)

Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Dasotraline Adult ADHD Study